• Schedule An Appointment
  • (631) 675-5075
  • Career Openings
  • Español 中國傳統的 简体中文
  • Locations
  • Care Team
  • Locations
  • Care Team
    • All Doctors
    • Medical Oncologists
    • Radiation Oncologists
    • Breast Surgeons
    • Surgical Oncologist
    • Support/Palliative
    • Behavioral Health
    • Registered Dietitian Nutritionists
    • Our APPs
  • Patients
    • Accepted Insurance
    • Appointments
    • Blood Disorders
    • Cancers
    • Carespace Portal
    • Fill my Prescription
    • Make A Payment
    • Mammography
    • Medical Marijuana
    • Patient Advocacy
    • Physical Therapy
    • Radiology
  • Professionals
    • Patient Referral
    • Clinical Trials
    • Our Research Center
    • Our Research Team
    • Career Opportunities
    • News & Events
    • NCCN Guidelines
    • Oncology Medical Home (OMH)
  • Research
    • About Research
    • Common Questions
    • Study Participation
    • Our Research Center
    • Our Research Team
    • Clinical Trials
  • About
    • About Us
    • Events
    • News & Updates
    • Our Leadership
    • Our Difference
    • Our Friends
    • Our Services
      • Medical Oncology
      • Radiation Oncology
      • Hematology
      • Fill My Prescription
      • Physical Therapy
      • Health & Wellness
      • Laboratory Testing
      • Personalized Medicine
      • Diagnostic Imaging
      • Other Services
    • Career Opportunities
      • Opportunities
      • Request for Educational Opportunities
    • Newsletters

MoonROSE: CDK2/4/6 Inhibitor GDC-4198 in Combination with Giredestrant for Patients with ER+, HER2- Metastatic Breast Cancer After Treatment with a CDK4/6 Inhibitor

Condition: Breast Cancer

Sponsor: Genentech, Inc.

Full Title
Protocol GO46021: A Phase Ib/II Multicenter, Open-label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination With Giredestrant in Comparison With Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2-negative Breast Cancer Who Have Previously Progressed During Or After a CDK4/6 Inhibitor

Study Treatment
Oral CDK2/4/6 inhibitor GDC-4198 as monotherapy or in combination with oral next generation SERD Giredestrant

Eligibility/Info
Eligible patients must have metastatic ER+, HER2- breast cancer that has been treated with a CDK4/6 inhibitor in the metastatic setting but has not been treated with chemotherapy in the metastatic setting.

Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Nostrand Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology


Go To Trial Homepage

Call Us

(631) 675-5075

Contact us today to request an appointment.

Virtual & Telemedicine available.

Request Appointment

Patient Links

  • Make An Appointment
  • Make A Payment
  • Fill My Prescription
  • Accepted Insurance
  • Medical Marijuana
  • Appointment Information
  • Physical Therapy
  • Patient Advocacy
  • Carespace Portal
  • Cancer Information

About

  • Our Story
  • Our Care Team
  • Locations
  • Careers & Job Openings
  • Newsletters
  • What Is Cancer?
  • What Are Blood Disorders?
  • What Is Oncology?
  • What Is Hematology?
  • Podcasts
  • Oncology Medical Home (OMH)

Research

  • About Research
  • Common Questions
  • Study Participation
  • Our Research Center
  • Our Research Team
  • Clinical Trials
  • Observational Studies
  • Cancer Resources
  • Blood Disorder Resources

Contact Us


info@nycancer.com

  • Terms and Conditions
  • Privacy Policy
  • HIPAA and Compliance
  • Healthix
© 2025 NYCancer.com